Literature DB >> 3191492

Snail neurons as a possible model for testing neurotoxic side effects of antitumor agents: paracrystal formation by Vinca alkaloids.

L J Müller1, C M Moorer-van Delft, E W Roubos.   

Abstract

The suitability of neurons of the freshwater snail Lymnaea stagnalis as a test system for the neurotoxic side effects of antitumour Vinca alkaloids has been investigated, by studying the process of paracrystal induction by Vinca antitumour agents. Three Vinca alkaloids have been compared: the natural vinblastine and vincristine and the semisynthetic vindesine. They appear to induce two types of inclusion. The first type is paracrystalline and has a rod-like shape with a width of 0.3-2.5 micron and a length of 1-10 micron. It consists of hexagonally arranged tubules with a lattice constant of approximately 28 nm. The second type appears as ladder-like profiles with a periodicity of approximately 30 nm. It is proposed that the ladder-like profiles are in fact helical structures and are precursors of the paracrystals. Both types of inclusion may fill up large parts of the axons; they are rare in axon terminals and almost absent from the neuronal somata. It has been concluded that the process of paracrystal induction by Vinca alkaloids in Lymnaea neurons is very much the same as in mammalian neurons and may be largely responsible for the neurotoxic effects of the Vinca drugs, because it impairs axonal transport of neuronal secretory granules. Apparently, in this respect vindesine behaves in a similar way as the conventional vincristine and vinblastine drugs. Vincristine induces clearly more paracrystals than vindesine, whereas the least paracrystals occur in vinblastine-treated material. These differences correlate with the different clinical neurotoxicities of these drugs. Therefore, because Lymnaea neurons can be considered as excellent model systems for studies of the functioning of neurons in general, it is expected that counting the number of paracrystals in Lymnaea nervous tissue will prove to be a good method to predict the degree of clinical neurotoxicity of newly developed antitumor Vinca alkaloids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191492

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis.

Authors:  H H Boer; C M Moorer-van Delft; L J Müller; B Kiburg; J B Vermorken; J J Heimans
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

2.  Investigation of anti-tumor mechanisms of K2154: characterization of tubulin isotypes, mitotic arrest and apoptotic machinery.

Authors:  Pin-Hsuan Lu; Fan-Lu Kung; Sheng-Chu Kuo; Shih-Chieh Chueh; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-11       Impact factor: 3.000

3.  Vinca-alkaloid neurotoxicity measured using an in vitro model.

Authors:  A A Geldof; A Minneboo; J J Heimans
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

Review 4.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

5.  Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy.

Authors:  A A Geldof
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Retardation of rat sciatic nerve regeneration after local application of minute doses of vincristine.

Authors:  G S Ruigt; M H den Brok
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Effects of the ACTH(4-9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U937 and U715.

Authors:  B Kiburg; A A van de Loosdrecht; K M Schweitzer; G J Ossenkoppele; L J Müller; J J Heimans; P C Huijgens
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.